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An effective response to the coronavirus disease 2019 (COVID-19) pandemic requires a better understanding of the biology of the 
infection and the identification of validated biomarker profiles that would increase the availability, accuracy, and speed of COVID-
19 testing. Here, we describe the strategic objectives and action lines of the European Alliance of Medical Research Infrastructures 
(AMRI), established to improve the research process and tackle challenges related to diagnostic tests and biomarker development. 
Recommendations include: the creation of a European taskforce for validation of novel diagnostic products, the definition and 
promotion of criteria for COVID-19 samples biobanking, the identification and validation of biomarkers as clinical endpoints for 
clinical trials, and the definition of immune biomarker signatures at different stages of the disease. An effective management of the 
COVID-19 pandemic is possible only if there is a high level of knowledge and coordination between the public and private sectors 
within a robust quality framework.
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The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pandemic has generated a fast response from the global 
scientific community, governmental organizations, the life sci-
ences industry, and healthcare providers. With unprecedented 
speed, a number of laboratory tests have been developed with 
the aim to facilitate easy and efficient detection of virus infec-
tion [1–4], and tests are emerging for the measurements of anti-
bodies for identifying past SARS-CoV-2 infections.
As the pandemic evolves, it is becoming clear that there is 
a gap between the ambition and the usefulness of these tests. 
Evidence continues to accumulate on the limitations of the cur-
rently available diagnostic and prognostic approaches [2–6].
Coronavirus disease 2019 (COVID-19) assays can be distin-
guished in (1) virus detection assays (nucleic acid and imaging 
based), (2) immunity assays (serological or immune cell based), 
and (3) prognostic assays reflecting severity of disease, com-
plications and degree of recovery (miscellaneous biomarker 
testing) [4, 7].
In particular, serological tests are becoming more relevant as 
they are able to detect past COVID-19 infections [8]. However, 
many open questions remain around each test’s specificity and 
sensitivity, which represents its validity and usefulness in a clin-
ical setting. The value of these tests, as with many other bio-
marker tests in healthcare and patient management, is one of 
today’s major challenges.
In addition to SARS-CoV-2 detection and testing of immune 
response, there is an urgent need to predict which patients 
will develop specific disease characteristics. Indeed, some in-
dividuals develop mild symptoms and others very severe ones 
for unknown reasons, and patients can differ dramatically in 
the degree and speed of their response following hospitaliza-
tion [7]. Recent studies showed how COVID-19 patients with 
comorbidities, such as hypertension or diabetes mellitus, are 
more likely to develop a more severe course and progression 
of the disease [9]. Differences in the immune response [10] or 
prior coronaviruses infections could also affect the COVID-19 
clinical course [11].
This heterogeneity of manifestations of SARS-CoV-2 infec-
tion constitutes one of the greatest challenges in managing the 
clinical consequences of the pandemic. Biomarker profiles are 
of vital importance to clinicians when evaluating treatment op-
tions, for defining the clinical course, and for close monitoring 
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Tools should enable population screening and the identifica-
tion of high-risk patients. Given the large interindividual het-
erogeneity, this can be achieved using biomarker signatures, 
composed of multiple analytes. Given their relevance in this 
context, robust and well-validated biomarkers are crucial to en-
able effective decision-making.
SARS-COV-2 TESTING: CURRENT SITUATION
SARS-CoV-2 and COVID-19 testing kits are designed to be used 
in routine laboratories and also at the point-of-care setting, with 
the ambition of shortening the diagnostic time window and 
thereby facilitating rapid identification of COVID-19 positive 
patients and contacts. In order to be effective, these kits must 
be based on validated biomarkers and biomarker assay formats 
that yield high sensitivity and specificity results, for instance, to 
distinguish an infected person from a noninfected one.
SARS-CoV-2 diagnostic tests are based on the detection of the 
viral genome (eg, reverse transcription polymerase chain reac-
tion (RT-PCR)-based methods, isothermal amplification assays 
and CRISPR [12–16]), viral proteins (eg, antigen-based test) [17, 
18], or antibodies against the virus (eg, serological test) [8].
Methods based on the viral genome detection, with their 
large range of applications, high sensitivity, and high sequence 
specificity, have become a routine and reliable technique for 
detecting [16].
To complement the viral genome tests, viral antigen tests 
have been developed. These tests allow the virus detection early 
in infection but display limitations on sensitivity and potential 
cross-reaction with other coronaviruses [17, 18].
Despite the fact that COVID-19 is a severe pandemic, many 
governments are leaning toward “mitigation” and “contain-
ment” as strategies. The overarching goal is for all countries to 
control the pandemic by slowing down the transmission and 
reducing mortality associated with COVID-19. Indeed, in the 
absence of a vaccine, reaching group immunity is no straight-
forward path with major ethical considerations as the societal 
consequences of achieving it are devastating [19]. Mobility and 
travel restrictions, social distancing, and the use of personal 
protective equipment have been introduced in order to reduce 
human-to-human transmission. The use of face masks in par-
ticular is enforced widely within the general population, to-
gether with hand hygiene.
Stopping the spread of COVID-19 requires finding and 
testing all suspected cases so that confirmed cases are promptly 
and effectively isolated and receive appropriate care. It is im-
portant that the close contacts of all confirmed cases are rapidly 
identified, quarantined, and medically monitored for the virus 
incubation period of up to 14 days.
Next to the need for well-validated and reliable diagnostic 
tests, this scenario demands high quality and reliable serolog-
ical tests, measuring the immune responses induced by past and 
new viral infection, in combination with tests addressing T-cell 
activity. These assays are important for understanding the preva-
lence of COVID-19 and whether the development of a humoral 
immune response to SARS-CoV-2 protects against the disease.
As the World Health Organization (WHO) clearly under-
lined, “Laboratory tests that detect antibodies to SARS-CoV-2 
in people, including rapid immunodiagnostic tests, need further 
validation to determine their accuracy and reliability” (https://
www.who.int/news-room/commentaries/detail/immunity-
passports-in-the-context-of-covid-19). Addressing these issues 
is crucial, as serological assays are critical for the patient care 
pathway and for the management and surveillance of the virus.
Limitations to the use and development of the tests described 
above include poor test sensitivity due to sample collection [14], 
poorly described reference material, low specificity, and lack 
of technical validation, and therefore a threat of false disease 
diagnosis.
Uncertainty in test sensitivity that lead to false-negative cases of 
COVID-19 likely constitutes a serious threat to the control of the 
pandemic. Indeed, false negative results are more weighty, because 
unrecognized infected persons may not be isolated and can infect 
others [4]. Because of this, some governments require RT-PCR 
test and quarantine for people who are considered close contacts 
of positive cases, with additional testing and isolation in case of 
negative results. Moreover, in presence of a strong epidemiological 
link to COVID-19 infection, paired serological tests (in the acute 
and convalescent phase) could support diagnosis [20].
Testing limitations are likely a result of combining several 
unknowns such as the lack of understanding of the biology of 
the disease, in particular its natural history and associated im-
mune response, a relatively low number of samples, and the use 
of novel laboratory test kits whose quality and accuracy has not 
been rigorously tested. Furthermore, the lack of rigorous study 
design and methodology to robustly validate the tests before de-
ployment affects the tests’ reliability and ultimately the correct-
ness of the clinical assessment.
URGENT NEED FOR VALIDATED BIOMARKERS
A collaborative global response for diagnostics, therapeutics, 
and vaccines development as well as the future management of 
the pandemic called the new Access to COVID-19 Tools (ACT) 
global accelerator has been launched in April. The ACT accel-
erator will require additional molecular tools to identify rele-
vant COVID-19 related biomarkers that will have a critical role 
in: (1) assessing the efficiency of future vaccines and/or thera-
peutics; (2) preventing and identifying clinical complications, 
in particular those related to the deadly immunological storm 
reaction, vascular activation and hemostasis control, and, (3) 
stratifying patients to define therapy targets and identify indi-
viduals at risk of infection, suitable for preventive interventions. 
Due to the complexity of the immune response, in-depth phe-
notypic analysis is necessary in order to identify specific bio-
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According to the GlobalData’s Biomarkers database, a large 
number of different biomarkers have been utilized for COVID-
19 trials for different purposes such as monitoring treatment 
response, predicting and monitoring treatment safety. However, 
only a few of them are validated for clinical application, with 
the risk that the results produced are not reliable and are not of 
much use for medical decision making.
Hematology laboratory and routine coagulation tests have 
made a significant contribution in the identification of useful 
prognostic markers as well as in predicting outcomes and re-
covery [21, 22]. Moreover, in the era of personalized medicine, 
biomarkers can enable the selection of appropriate treatment 
for COVID-19 infected patients. Biomarkers of inflammation 
such as interleukin (IL)-6 and IL-10 [23], of cardiac injury [24], 
of liver and kidney function [25, 26], as well as of coagulation 
measures [27], are significantly elevated in patients with both 
severe and fatal forms of COVID-19. Moreover, it has been 
assumed from studies in severe acute respiratory syndrome 
(SARS) and Middle East respiratory syndrome (MERS) patients 
that memory T cells, induced by the contact with previous 
pathogens from the coronavirus family, may have the poten-
tial to recognize SARS-CoV-2. Hence, features and distribution 
of preexisting T cells could be used as markers for explaining 
some of the differences in infection rates or pathology observed 
during this pandemic [11].
The mentioned markers could support patient stratifica-
tion and represent objective and standardized criteria to guide 
therapy and allocate resources.
Although the postrecovery course of the COVID-19 disease 
is not clear yet, limited observations demonstrated that they are 
at risk of psychological and physical complications of the di-
sease itself, as well as treatment-related lung damage and other 
organ injuries [28–30]. Biomarker signatures can play a key role 
in the management of the post-COVID-19 patients, predicting 
medium and long-term clinical outcomes.
More insights on the biological processes and replication 
studies are crucial before the adoption of any molecule and pa-
rameter in the clinical setting.
The coming months will be critical for accelerating a 
COVID-19 biomarker pipeline that will enable diagnostic and 
prognostic profiles, provide reliable end points for clinical trials, 
assess treatment response and allow vaccine candidate selec-
tion, together with supporting healthcare systems with tailored 
strategies and patient-centred interventions.
HOW TO OPTIMIZE THE RESEARCH PROCESS: THE 
POINT OF VIEW OF EUROPEAN MEDICAL RESEARCH 
INFRASTRUCTURES
In order to structurally address the issues above, a long-term 
vision is necessary. The optimization and the acceleration of the 
research process requires a high level of knowledge and coor-
dination, as well as the application of standards and quality to 
reduce uncertainty along the biomarker pipeline [31]. This is 
possible only if there is an effective interaction between private-
public networks. In Europe this collaboration is facilitated by 
research infrastructures. In particular, the Alliance of Medical 
Research Infrastructures (AMRI, https://bit.ly/2FitLu9), in-
cluding EATRIS-ERIC (focused on translational medicine, 
https://eatris.eu/), ECRIN-ERIC (focused on clinical research, 
https://www.ecrin.org/) and BBMRI-ERIC (focused on 
biobanking https://www.bbmri-eric.eu/) provides resources 
and services for the medical research communities to conduct 
research and foster innovation. During the present health crisis, 
substantial public funding has become available for research in 
diagnostics, treatments, and vaccines for the new coronavirus 
disease, and AMRI has worked to accelerate and manage in-
ternational research collaborations on COVID-19, acknow-
ledging that the challenge is a global one. The medical research 
infrastructures have made a significant effort to share know-
ledge and to ensure robustness of the COVID-19 related pro-
ject outcomes [32]. In addition, thanks to its expertise as well as 
its culture in quality standards and reproducibility, the Alliance 
identified several action lines (Table 1) to optimize the research 
process and to address issues related to diagnostic/prognostic 
tests and biomarker development. Their main strategic object-
ives are: (1) to establish a European taskforce for validation of 
novel diagnostic products; (2) to define and promote criteria 
for COVID-19 sample handling, data collection, and biobank 
management including ethical considerations; (3) to validate 
novel diagnostic approaches; (4) to identify and validate bio-
markers as clinical endpoints for clinical trials; and (5) to de-
fine the biomarker profile determining the innate and acquired 
immune response to the infection and establish immune signa-
tures at different stages of the disease. These actions are highly 
relevant for an effective response from the research community 
to the COVID-19 pandemic. Only with close collaboration in 
these key areas will we be able to efficiently support the bio-
marker R&D process, helping to understand antigen response 
mechanisms, inform vaccine development, and enable antiviral 
drug design.
CONCLUSIONS
COVID-19 research is still in its early stages, and we need 
further research worldwide to better face this pandemic. We 
still need to learn about the biology of the disease and the var-
iable response that patients display in their disease manifes-
tation and recovery. We expect that the process of biomarker 
discovery and validation will largely guide an accelerated 
translational strategy to address this global health crisis. 
A  standardized pathway approach toward the biomarker 
validation process is thus becoming increasingly important. 
Quality and reproducibility are essential for translating basic 
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Table 1. Overview of Actions Recommended by Alliance of Medical Research Infrastructures (AMRI)
Strategic Objective Recommended Actions
(1)  Establish a European taskforce for validation of 
novel diagnostic products
• Definition of joint evaluation of novel testing methodologies
• Definition of recommendations for statistical study design, including appropriate end points
• Focused efforts on stratification of patients to be included based on harmonized diagnosis 
criteria and standardized diagnosis biomarkers
• Promotion of cross-border multicentric diagnostic studies
• Creation of standardized protocols so that independent studies can generate interoperable 
data to increase statistical robustness
• Include regulators early in the process and update constantly on progress
(2)  Define criteria for COVID-19 sample handling, data 
collection and biobank management including 
ethical considerations
• Development of guidelines on the ethical aspects for sampling and data sharing in COVID-19 
patients
• Definition of specific protocols for protection measures in the context of samples handling
• Definition of appropriated samples (origin and source) to be used for diagnostic techniques
• Provide guidelines on relevant clinical data collection
• Definition of technical controls for samples before the use in each application
• Provide guidelines for long-term storage of biological samples (including autopsy samples), 
including minimization of RNA-degradation
• Definition of specific protocols for COVID-19 autopsy samples
(3) Validate novel diagnostic approaches • Development of appropriate control materials from diverse biological matrix
• Definition of standards for amplification specificity
• Use of preamplification controls
• Improve accuracy of CRISPR-Cas cleavage and read-out system
• Improve sensitivity of nonamplification-based technologies
• Provide easy and accurate novel point of care portable detection devices
(4)  Identify and validate biomarkers as clinical 
endpoints for clinical trials
• Development of tools for clinical data analysis for identifying prognosis biomarkers and poten-
tial endpoint biomarkers
• Development of easy, reliable, and standardized detection methods of biomarkers to be used 
in clinical trials
• Development of consensus guidelines for use of biomarker-based patient stratification across 
Europe in multicentric studies
• Identification of individual immunoprofiling signatures for personalized therapies
(5)  Define the biomarker profile determining the 
innate and acquired immune response to the in-
fection, establish immune signatures at different 
stages of the disease
• Development of quantification methods for serum immunoglobulins: reference values defini-
tion
• PBL immunoprofiling by appropriated cell markers: reference values definition
• Cytokines profiling: SNPs in relevant cytokines (IL-6): reference values definition
• Complement cascade and hemostasis regulators quantification: reference values definition
• Identification of cofactors/comorbidities affecting immune response: autoimmune diseases, 
suppressor treatments
• Development of predictive immuneprofiling signatures for the identification of patients at risk 
of cytokine storms
Abbreviations: COVID-19, coronavirus disease 2019; IL, interleukin; PBL, project-based learning; SNP, single nucleotide polymorphism.
this approach is an effective response to the pandemic guar-
anteed. Significant efforts and resources have been invested 
in the development of biomarkers for COVID-19 and AMRI 
urges that research must be of good quality, providing robust, 
ethical evidence that stands up to scrutiny and can be used to 
inform policy making. For COVID-19 management, struc-
tural use of the relevant research infrastructures is strongly 
advised, as they play an important role in centralized man-
agement of biomarkers R&D pipelines, biobanking, and clin-
ical trials. The collective efforts of AMRI and collaborative 
actions of the scientific community will create high-quality 
knowledge that is openly available and will bring a better un-
derstanding of SARS-CoV-2, with benefits for all.
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